TELA Bio Reports Q4 Earnings Miss, Q1 Revenue Estimates Unchanged

TELA Bio, Inc. reported a Q4 loss of $0.16 per share, beating the Zacks Consensus Estimate of a loss of $0.18. The company's revenue of $20.87 million missed the Zacks Consensus Estimate by 0.62%. TELA Bio shares have lost 29.7% since the beginning of the year. The company's earnings outlook is expected to be mixed, with a Zacks Rank #3 (Hold) for the stock.